

CSD/BSE&NSE/CC/2025-26  
November 05, 2025

To  
The Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**Scrip Code: 543064**

**Scrip Symbol: COHANCE**

Dear Sir/Madam,

**Sub: Schedule of Conference Call for Investors and analysts**

With reference to above subject, please find enclosed intimation regarding schedule of conference call for investors and analysts on Wednesday, November 12, 2025 at 07.00 p.m. IST to discuss the Un-audited Financial Results for Q2 & H1FY26, to be considered on November 12, 2025.

This is for your information and record.

Thanking You.

Yours faithfully,  
For **Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Kundan Kumar Jha**  
*Company Secretary, Compliance Officer and Head-Legal*

Encl: as above

---

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad  
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.  
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,  
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.  
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | Company Email: [info@suvenpharm.com](mailto:info@suvenpharm.com)




## Cohance Lifesciences Limited's Q2 and H1FY26 Results Conference Call on Wednesday, November 12, 2025, at 7.00 pm IST.

Cohance Lifesciences Ltd. will organize a conference call for investors and analysts on Wednesday, November 12, 2025 at 7.00 pm IST.

The management team will be represented by Mr. Vivek Sharma (Executive Chairman), Mr. Himanshu Agarwal (Whole-time Director and Chief Financial Officer) and Cyndrella Carvalho (Head – IR).

The conference call will be initiated with a brief management discussion on the Q2 & H1FY26 results to be declared on Wednesday, November 12, 2025 followed by an interactive Question & Answer session.

### Details of the conference call are as follows:

<b>Timing</b>	7.00 pm IST on Wednesday, November 12, 2025
<b>Conference dial-in</b>	
<b>Primary number</b>	+91 22 6280 1141 / +91 22 7115 8042
<b>Singapore Toll Free Number</b>	800 101 2045
<b>Hong Kong Toll Free Number</b>	800 964 448
<b>USA Toll Free Number</b>	1 866 746 2133
<b>UK Toll Free Number</b>	0 808 101 1573
<b>Pre-registration</b>	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link:</p> <div>  <a href="#">Click here to ExpressJoin the Call</a> </div> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode &amp; pin to connect to call</p>

Please dial the above number 5-10 minutes prior to the scheduled start to ensure that you are connected to the call on time.

### For more information, please contact:

**Cyndrella Carvalho, Head - Investor Relations,**  
**Cohance Lifesciences Limited**  
**Tel:** 040 2354 3311  
**Email:** [cyndrella.carvalho@cohance.com](mailto:cyndrella.carvalho@cohance.com)

**Gavin Desa / Rishab Barar**  
**CDR India**  
**Tel:** +91 98206 37649/ +91 77770 35061  
**Email:** [gavin@cdr-india.com](mailto:gavin@cdr-india.com)  
[rishab@cdr-india.com](mailto:rishab@cdr-india.com)

**Cohance Lifesciences Limited**  
 (Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSILC, Raidurg, Hyderabad – 500081, Telangana, India.  
 Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai – 400093, Maharashtra, India.  
 Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | Company Email: [info@suvenpharm.com](mailto:info@suvenpharm.com)